GSK Lapatinib Breast Cancer Development Shifts To Front-Line Setting
GlaxoSmithKline will shift its plans for the breast cancer agent lapatinib to focus on front-line use rather than refractory patients, the company said May 15
GlaxoSmithKline will shift its plans for the breast cancer agent lapatinib to focus on front-line use rather than refractory patients, the company said May 15